netakimab vs vunakizumab

NCT03598751 · Phase 3 · completed

This was a randomized, double-blind, placebo-controlled trial of 194 patients. The proportion of patients achieving a validated joint-response measure (ACR20) was overwhelmingly higher with netakimab than placebo, a gap large enough to leave no real doubt about the direction of the effect even though a formal statistical test was not reported in the source used.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

NCT05055934 · Phase 2 · completed

The study was randomized, quadruple-blind, placebo-controlled, and included 112 participants, using the clinical ACR20 improvement measure as its primary endpoint. Because the registry does not report whether the primary endpoint was met, the trial provides well-designed but currently incomplete evidence.

NCT03390101 · Phase 3 · completed

This was a randomized, quadruple-blind, placebo-controlled trial with 213 participants and a clinical psoriasis endpoint (PASI 75) assessed at week 12. Results were not posted at the time of grading; the key result shown was recorded subsequently from the registry record.

NCT04839016 · Phase 3 · status unknown

This randomised, double-blind, placebo-controlled trial in 660 patients with moderate-to-severe plaque psoriasis reported PASI 90 in 76.8% of patients on vunakizumab against 0.9% on placebo at week 12, with sPGA 0/1 in 71.8% against 0.4%, both standard measures of skin clearance.